The ANXA2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line. This product features a heterogeneous pool of cells with targeted disruption of the ANXA2 gene, providing a robust model for studying annexin A2-dependent cellular processes without the limitations of monoclonal selection. These cells enable functional analyses of ANXA2 in fibrinolysis, cell migration, and signal transduction pathways.
The parental A-549 cell line is a widely used human lung adenocarcinoma epithelial model originally derived from a 58-year-old Caucasian male. These cells exhibit characteristics of alveolar type II pneumocytes and serve as a prominent system for studying non-small cell lung cancer (NSCLC) biology, respiratory epithelial function, and cancer cell signaling. A-549 cells are particularly valued for their well-characterized responses to growth factors, cytokines, and therapeutic agents, making them an ideal background for dissecting the molecular mechanisms of lung cancer progression and drug response.
ANXA2 encodes annexin A2, a calcium-dependent phospholipid-binding protein regulating membrane organization, endocytosis, exocytosis, and actin dynamics. As a key component of the annexin A2-S100A10 complex, ANXA2 functions as a receptor for plasminogen and tissue plasminogen activator, facilitating localized plasmin generation and extracellular matrix degradation. ANXA2 also participates in EGFR signaling, interacting with EGFR and contributing to downstream activation of MAPK/ERK and NF-??B pathways. Transcriptional regulation by EGF, TGF-??, STAT3, and MYC controls ANXA2 expression, which in turn promotes MMP2 and MMP9 production, driving epithelial-mesenchymal transition and cell invasion. Interaction with integrins ITGAV and ITGB1 further supports cell adhesion and migration.
In the A-549 lung adenocarcinoma model, ANXA2 knockout disrupts the ANXA2-S100A10 complex, impairing tissue plasminogen activator-mediated plasminogen activation and subsequent plasmin generation. This attenuation reduces extracellular matrix degradation and inhibits cell migration and invasion. Furthermore, loss of ANXA2 dampens EGFR transactivation and downstream MAPK/NF-??B signaling, leading to decreased MMP2 and MMP9 expression and suppression of EMT markers such as SNAI1 and Vimentin. These molecular alterations highlight the critical role of ANXA2 in maintaining the metastatic phenotype of lung cancer cells, making this knockout model a powerful tool for dissecting the interplay between fibrinolytic and oncogenic signaling pathways.
This polyclonal ANXA2 knockout cell product is suited for a broad array of experimental applications, including transwell-based migration and invasion assays, gelatin zymography for MMP activity, plasmin generation assays, and phospho-analysis of EGFR signaling components. Researchers can employ western blotting or RT-qPCR to validate ANXA2 disruption and assess downstream target expression, while immunofluorescence can reveal altered localization of interacting proteins such as S100A10 and EGFR. The model also facilitates drug sensitivity testing and screening of ANXA2-targeted therapeutic compounds. For further details and technical support, please contact Ascent Research.
